Can Novarel administration affect the outcomes of preimplantation genetic testing for aneuploidy (PGT-A), and how does it influence embryo quality and testing synchronization?
Gaurav ChauhanContributor
Can Novarel administration affect the outcomes of preimplantation genetic testing for aneuploidy (PGT-A)?
Share
Novarel, a brand of hCG, is used in IVF to mature eggs but does not directly affect PGT-A results or embryo quality. It ensures timely egg retrieval for synchronization.
Novarel, a form of hCG, doesn’t directly affect PGT-A outcomes but influences embryo quality by improving endometrial receptivity, aiding implantation synchronization.
Novarel use in IVF protocols primarily affects embryo implantation rather than genetic testing like PGT-A, although optimal embryo development enhances test accuracy.
Administering Novarel affects neither the direct outcomes of PGT-A nor embryo genetics, but its role in promoting ovulation can lead to higher quality embryos, indirectly benefiting PGT-A results.